Efficacy of Recombinant Factor VIIa (rVIIa) in Surgical Procedures in Haemophilia A Patients with Inhibitors and Congenital Factor VII Deficiency

  • J. Ingerslev
  • O. Sneppen
  • L. Knudsen
  • S. Sindet-Pedersen
Conference paper


Since bleeding can not safely be controlled by ordinary factor VIII substitution in such cases, the presence on inhibitors against factor VIII is a significant complication in patients with haemophilia A, particularly when highly titered factor VIII antibodies are present. Reported incidences of inhibitors amongst haemophilia A patients have varied from a few percent and up to around 50%. In our centre, the prevalence of persistent high responding patients that have either failed to achieve immune tolerance using continuous high doses or factor VIII or where such treatment has not been attempted is 5/162 (3%) of our present haemophilia A population.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Samsjödin L, Heijnen L, Mauser-Bunschoten E et al (1981) Effect of activated prothrombin complex concentrate (FEIBA) on joint and muslce bleeding in patients with haemophilia A and antibodies to factor VIII. New Engl J Med 305: 717–721CrossRefGoogle Scholar
  2. 2.
    Sullivan DW, Purdy LJ, Billingham M et al (1984) Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A. Pediatrics 74: 279PubMedGoogle Scholar
  3. 3.
    Penner JA (1984) Treatment of inhibitor patients with activated prothrombin complex concentrates. In: Hoyer LW (ed) Factor VIII inhibitors. Liss, New York, pp 291–308Google Scholar
  4. 4.
    Christiansen SE, Ingerslev J, Wallevik K et al (1986) Management of anterior compartment syndrome in two high responder patients with activated prothrombin complex concentrate. Thromb Res 42: 707–712PubMedCrossRefGoogle Scholar
  5. 5.
    Sindet-Pedersen S, Stenbjerg S, Ingerslev J (1987) Treatment of bilateral fracture of the mandible in a hemophilic patient with inhibitor to factor VIII. J Oral Maxillofac Surg 45: 537–540PubMedCrossRefGoogle Scholar
  6. 6.
    Hedner U, Glazer S (1992) Management of hemophilia patients with inhibitors. Hematol Oncol Clin North Am 6: 1035–1046PubMedGoogle Scholar
  7. 7.
    Hedner U, Schulman S, Alberts A et al (1988) Successful use of rFVIIa in a patient with severe haemophilia A subjected to synovectomy. Lancet 2: 1193PubMedCrossRefGoogle Scholar
  8. 8.
    Ingerslev J, Feldstedt M, Sindet-Pedersen S (1991) Control of haermostasis with recombinant factor Vila in patient with inhibitors to FVIII. Lancet 338: 831–832PubMedCrossRefGoogle Scholar
  9. 9.
    Kjaersgaard Andersen P, Christiansen SE, Ingerslev J, Sneepen O (1990) Total knee arthroplasty in hemophilia A patients. Clin Orthop 258: 137–146Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • J. Ingerslev
  • O. Sneppen
  • L. Knudsen
  • S. Sindet-Pedersen

There are no affiliations available

Personalised recommendations